CIEDs remain integral to HF management despite adoption challenges from limited randomized evidence.
View Full Paper
Ask AI
Bookmark
Share
Why the study?
To summarize current and potential future indications, emerging technologies, and implementation challenges of cardiac implantable electronic devices in heart failure management.
Design
Review
Key result
Cardiac implantable electronic devices, including conduction system pacing and novel defibrillators, are integral to heart failure management, though adoption is challenged by limited randomized evidence.
Authors
Discussion
Loading...
Member takes
Overview
Biventricular pacing remains first-line; leaves open adoption of left bundle branch area pacing pending randomized trials.
Key Points
- To review current indications, emerging technologies, and practical barriers in the implementation of cardiac implantable electronic devices for heart failure management.
- Synthesized clinical evidence on conduction system pacing, leadless pacing systems, extravascular defibrillators, and remote hemodynamic monitoring.
- Assessed implementation challenges including procedural complexity, healthcare disparities, and evidence gaps across heart failure phenotypes.
- Left bundle branch area pacing and leadless pacing systems demonstrate potential to replace conventional right ventricular pacing and optimize cardiac resynchronization therapy.
- Subcutaneous and extravascular implantable cardioverter-defibrillators provide effective sudden cardiac death prevention while reducing transvenous lead-associated complications.
- Clinical adoption of novel pacing indications and monitoring tools remains constrained by limited randomized clinical trial evidence and unequal healthcare access.
Structured PICO
P
Population
Patients with heart failure requiring cardiac implantable electronic devices for bradyarrhythmias, cardiac resynchronization therapy, or sudden cardiac death prevention
I
Intervention
Cardiac implantable electronic devices (including biventricular pacing, conduction system pacing such as left bundle branch area pacing, leadless pacemakers, and implantable cardioverter-defibrillators)
C
Comparator
Conventional right ventricular pacing or standard medical therapy
This review highlights the evolving landscape of device therapy in heart failure, emphasizing the shift towards physiological conduction system pacing and the need for ongoing randomized trials to establish the clinical benefit of these emerging technologies.
Limitations
- Limited randomized evidence for emerging technologies
- Procedural complexity
- Substantial disparities in access and implementation across healthcare systems
- limited randomized evidence for emerging technologies
- procedural complexity
- substantial disparities in access and implementation across healthcare systems
Cite This Study
Žižek et al. (2026) conducted a review in Heart Failure. Cardiac implantable electronic devices (CIEDs) was evaluated. Cardiac implantable electronic devices, including conduction system pacing and novel defibrillators, are integral to heart failure management, though adoption is challenged by limited randomized evidence.
View Full Paper
Ask AI
Bookmark
Share